New pill shows promise in early trial for Tough-to-Treat cancers
NCT ID NCT04857372
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests an oral drug called IAG933 in adults with advanced mesothelioma and certain other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 137 participants will take the drug by mouth, and researchers will monitor side effects and tumor response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT EPITHELIOID HEMANGIOENDOTHELIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030 4009, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Novartis Investigative Site
Melbourne, Victoria, 3000, Australia
-
Novartis Investigative Site
Montreal, Quebec, H2W 1T8, Canada
-
Novartis Investigative Site
Villejuif, 94800, France
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Milan, MI, 20133, Italy
-
Novartis Investigative Site
Rozzano, MI, 20089, Italy
-
Novartis Investigative Site
Chuo Ku, Tokyo, 1040045, Japan
-
Novartis Investigative Site
Rotterdam, South Holland, 3015 GD, Netherlands
-
Novartis Investigative Site
Barcelona, 08035, Spain
-
Novartis Investigative Site
Zurich, 8091, Switzerland
-
Novartis Investigative Site
Manchester, M20 2BX, United Kingdom
-
Uni of Chi Medi Ctr Hema and Onco
Chicago, Illinois, 60637, United States
-
University of California LA
Los Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Abdominal chemotherapy after surgery may improve mesothelioma outcomes
- New imaging tracer could spot hidden cancers and fibrosis in one scan
- Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
- Engineered immune cells take aim at Mesothelin-Positive tumors
- Frailty check could predict chemo danger for seniors